Published in Diabetes Ther on July 21, 2011
Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. Vasc Health Risk Manag (2013) 1.05
Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev (2013) 0.87
Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus. Pancreas (2016) 0.75
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 15.76
The biology of incretin hormones. Cell Metab (2006) 8.92
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med (2007) 8.31
Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med (2009) 7.08
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest (1993) 5.06
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet (2010) 4.89
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med (2005) 4.88
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia (2009) 4.81
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia (1986) 4.54
Pathogenesis of type 2 diabetes mellitus. Med Clin North Am (2004) 4.44
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med (2010) 4.03
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia (2006) 3.31
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest (1998) 3.18
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care (2007) 3.02
Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care (2009) 2.81
The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes (1985) 2.46
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab (2010) 2.30
Insulin-associated weight gain in diabetes--causes, effects and coping strategies. Diabetes Obes Metab (2007) 2.24
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab (2009) 2.19
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab (2002) 2.18
Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci (1993) 2.16
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev (2008) 2.10
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia (2007) 2.01
Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care (2004) 1.97
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia (2002) 1.86
Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes (2011) 1.74
Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 1.72
Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care (2010) 1.59
Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia (2005) 1.51
Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci (2006) 1.47
GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab (2011) 1.40
Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes (2010) 1.39
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes (2004) 1.37
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab (2009) 1.37
Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf (2007) 1.32
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res (2008) 1.19
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab (2011) 1.16
Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther (2009) 1.15
Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab (2004) 1.11
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol (2006) 1.09
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med (2010) 1.06
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care (2010) 1.06
Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos (2010) 1.05
Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes (2004) 1.04
Time for testing incretin therapies in early type 1 diabetes? J Clin Endocrinol Metab (2010) 1.04
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab (2011) 1.03
Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res (2008) 1.02
Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res (2008) 1.01
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag (2008) 0.94
Insulin detemir: A historical perspective on a modern basal insulin analogue. Prim Care Diabetes (2010) 0.91
Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism (2010) 0.88
Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther (2011) 0.87
Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu (2007) 0.86
Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes (2008) 0.84
The incretin pathway as a new therapeutic target for obesity. Maturitas (2010) 0.83
Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diabet Med (1996) 0.83
A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract (1994) 0.82
Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. Regul Pept (2010) 0.78
Can therapies that target the incretin system improve our ability to treat type 2 diabetes? J Natl Med Assoc (2010) 0.76
Insulin use in elderly adults: risk of hypoglycemia and strategies for care. J Am Geriatr Soc (2012) 1.07
Starvation-induced true diabetic euglycemic ketoacidosis in severe depression. J Gen Intern Med (2008) 1.05
Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin (2011) 1.02
Painful cutaneous lesions, renal failure and urgent parathyroidectomy. J Nephrol (2002) 0.96
Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care (2012) 0.95
The English national risk-reduction programme for preservation of sight in diabetes. Mol Cell Biochem (2004) 0.90
The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS One (2013) 0.85
Insulin aspart: a review. Expert Opin Drug Metab Toxicol (2006) 0.80
A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK. J Med Econ (2014) 0.80
Lymphocytic hypophysitis occurring simultaneously with a functioning pituitary adenoma. Endocr J (2008) 0.79
Iris ectopic thyroid tissue: report of a case. Arch Ophthalmol (2006) 0.78
Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study. BMC Endocr Disord (2014) 0.76
Evaluation of insulin use and value for money in type 2 diabetes in the United kingdom. Diabetes Ther (2013) 0.76
[Management of type 2 diabetes: from guidelines to clinical practice]. Med Clin (Barc) (2010) 0.75